Kennedy receives $570,600 NCI award for cancer research

Kennedy, Eileen-h.portrait

September 22, 2011

Sheila Roberson

Sheila Roberson

Public Relations Coordinator

Recent and archived articles by Sheila Roberson

College of Pharmacy
Work: 706-542-5303

Eileen Kennedy

Eileen Kennedy

Assistant Professor

Pharmaceutical and Biomedical Sciences
College of Pharmacy
Work: 706/542-6497


  • magnify Kennedy, Eileen-h.portrait

    Eileen Kennedy

Scroll Left 1 Scroll Right

Related Sites

Athens, Ga. - Eileen Kennedy, assistant professor of pharmaceutical and biomedical sciences in the University of Georgia College of Pharmacy, received a National Cancer Institute Transition Career Development Award from the National Institutes of Health for more than $570,600 over the next three years. Her project will look at specific mechanisms related to breast cancer.

The award is designed to help academic professionals working in cancer research transition from the mentored stage to the independent stage of their careers. Investigators must be within the first two years of their first independent cancer research positions. The award gives them protected time through salary and research support for three years, in order to help them initiate and develop their independently supported cancer research programs.

Additionally, the award helps assure that a diverse pool of highly trained scientists from under-represented populations are available in adequate numbers and in appropriate research areas to address the nation's biomedical, behavioral and clinical research needs.

Kennedy joined the College of Pharmacy in 2010. Her cancer research focuses on studying spatiotemporal regulation of kinases as it relates to cancer. Kinases are enzymes that help regulate signaling processes. They have been implicated in development and disease issues, including cancer.

A-kinase anchoring proteins act as a regulatory mechanism for some kinases, promoting subcellular localization near specific targets. Although AKAP mutations have been linked to cancer, it isn't clear how these subcellular mislocalizations lead to disease.

Kennedy's goal is to develop synthetic agents to use as investigative tools. She hopes to disrupt protein-protein interactions mediated by AKAPs in order to uncover specific cell signaling events in breast cancer.

Filed under: Medical Science, Cancer

Media Relations

Executive Director for Media Communications
Greg Trevor

706 / 542-8025
Executive Editor for Media Relations
David Bill

706 / 542-9150
Media Relations Coordinator
Sara Freeland

706 / 542-8077
Media Relations Coordinator for Broadcast
Melissa Jackson

706 / 542-8089

Open Records

Open Records Manager
Bob Taylor

706 / 542-8095